Navigation Links
Recruitment Completed in Ofatumumab NHL Pivotal Study
Date:9/23/2008

Summary: Genmab has Completed Recruitment of Patients in the Phase III

Study of Ofatumumab in Rituximab Refractory Follicular NHL

COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these patients will be included in the primary efficacy analysis. An additional 31 patients were recruited at a 500 mg dose level prior to amending the study design to include only one dose. Data from these patients will be evaluated for safety and supportive efficacy analysis.

"We have now recruited the last patient into the study and keenly await the results which we hope will show a benefit for follicular NHL patients who need a new treatment option," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site)of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.

About the trial

Patients in this study will receive one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab. Disease status will be assessed every 3 months until month 24.

The objective of the study is to determine the efficacy and safety of ofatumumab in rituximab refractory follicular NHL. The primary endpoint of the study is objective response
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
5. Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
6. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Genmab Reaches Milestone in Ofatumumab Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... PALO ALTO, Calif. , Sept. 30, 2014 ... early-stage investment group focused on supporting promising emerging ... companies, has been named the Top Angel Investment ... CB Insights as the best performer out of ... that included: historical performance, network strength (connections), selection ...
(Date:9/30/2014)... DIEGO , Sept. 30, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... Liver Model has been selected as a finalist in ... 2014 Most Innovative New Product Awards, sponsored by ... of innovative technology and life sciences products in ...
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
Breaking Medicine Technology:Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 2Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 3Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3
... RYE, N.Y., Oct. 14 Curemark, LLC, a drug research ... announced that it has enrolled the first patients in Phase ... first clinical trial patients have been enrolled at Lake Mary ... sites with a total 170 children across the country. , ...
... Cardiva Medical, Inc. announces today that its President, Glenn ... Chief Executive Officer at Innovative Energy, Inc., an alternative energy ... Medical stated, "I would like to thank Glenn for his ... his tenure as President, we have transformed Cardiva from an ...
Cached Medicine Technology:Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment 2Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc. 2Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc. 3
(Date:9/30/2014)... AutoTex PINK proudly offers pink ... in support of breast cancer awareness and research in ... non-profits to “go pink” -- supporting walks, runs and ... a woman-owned company that is among the nation’s leading ... partnering with their customers to raise breast cancer awareness ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Teeth replacement ... Dental Art Institute in Oxnard and Thousand Oaks, Calif., ... and tomorrow to provide training on full mouth rehabilitation. ... work, placing implants, providing cosmetic dentistry, correcting bite issues, ... said. , Dr. Jivraj, who has traveled to India ...
(Date:9/30/2014)... September 30, 2014 Loffler Companies, ... business technology and services was recognized by BEI ... Effectiveness (FCE) in 2013. This prestigious rating means ... first time and for an extended period following, ... than 20 years BEI Services has been the ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness ... courageous battles, Incredible Veins, Body & Skin is offering ... Cynosure. , “For cancer patients who receive radiation ... on their skin to accurately aim the radiation on ... survivors, they decide to have their tattoo removed as ...
(Date:9/30/2014)... 30, 2014 Julie Kuriakose, ... Allergy , will discuss how restaurants can become more ... special dietary restrictions at the 2014 Allergy Eats ... Professionals, October 21 in New York City. , “I’m ... topic to such an engaged industry audience. As food ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... Children,s Health Fund (CHF) strongly supports the health ... its steadfast commitment to this momentous effort.  We believe that ... especially for children.  The action taken shows an unprecedented effort ... well-being of all children in this country.  CHF thanks House ...
... ) today announced it will participate in the Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference in Phoenix, Ariz. , on March 24-26, 2010 . , ... , ... ... ...
... Living wills and surrogate decision makers account for only ... making medical decisions for hospitalized patients lacking the capability to ... Researchers who queried 281 physicians report their conclusions ... of the Journal of the American Geriatrics Society . ...
... AF Stat a collaboration of healthcare leaders ... of people affected by atrial fibrillation (AFib) today ... widget to help healthcare practitioners better explain the risks ... The most common form of heart arrhythmia, AFib affects ...
... , ... the launch of Website Realizer, an efficient solution to reduce the costs for building a ... looking website without writing a single line of code. , ... (PRWEB) March 22, 2010 -- Adritech Software has announced the ...
... fewer irritants than lighter brews, researchers find , ... coffee-lovers with delicate stomachs, scientists may have found a ... gastrointestinal discomfort. , European researchers studying stomach-irritating chemicals in ... production in the stomach. , "The major import of ...
Cached Medicine News:Health News:Statement by Irwin Redlener, MD, President, Children's Health Fund on Passage of a Health Care Reform Package by the House 2Health News:Statement by Irwin Redlener, MD, President, Children's Health Fund on Passage of a Health Care Reform Package by the House 3Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 2Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 3Health News:Numerous factors weighed when patients cannot make their own decisions 2Health News:'AFib Educator' app and widget offers patient dialogue tool for complex cardiovascular disease 2Health News:Adritech Software Releases Website Realizer, a Website Builder to Create Websites without Any Programming Knowledge 2Health News:Coming Soon: A Low-Heartburn Coffee? 2Health News:Coming Soon: A Low-Heartburn Coffee? 3
The WatchMate ID model displays multiple alarms locally with resident ID numbers and this information, along with residents names, can be displayed at a central station. Alarms may be cleared locall...
... Radianse indoor positioning ... measure of where and ... patients flow through care ... data provides intelligence that ...
... supports patient safety by providing patient ... patients are in the right place ... the exact patient location when a ... Measure patient flow times to identify ...
... VACUETTE Blood Collection Needles are preominantly used ... for single-use. The colour of the needle ... individual needle gauges. For example, yellow symbolises ... green 21 G (0.80 mm) and black ...
Medicine Products: